title: Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis.
abstract: Several studies have suggested that diacylglycerol can affect the induction of apoptosis induced by toxicants and ceramide. The present study demonstrates that clinically relevant concentrations of the chemotherapeutic drugs daunorubicin and mitoxantrone (0.2-1 microM) transiently stimulated concurrently with sphingomyelin-derived ceramide generation and diacylglycerol and phosphorylcholine production within 4 to 10 min via phospholipase C hydrolysis of phosphatidylcholine. Pretreatment of cells with the xanthogenate compound D609, a potent inhibitor of phosphatidylcholine-phospholipase C, led to significant inhibition of drug triggered diacylglycerol and phosphorylcholine production and to a sustained increase in ceramide levels for a period up to 2 h. Moreover, D609 pretreatment induced both cell death and ceramide generation at daunorubicin and mitoxantrone concentrations previously shown to be ineffective (i.e., 0.1 microM). These results underline the importance of diacylglycerol in the regulation of programmed cell death and strongly argue for a balance between apoptotic (ceramide) and survival (diacylglycerol) signal transducers.
authors.affiliation: Contrat Jeune Formation Institut National de la Santé et de la Recherche Medicale 95-03, Institut Claudius Régaud, Toulouse, France. inserm@icr.fnclcc.fr
authors.forename: A
authors.initials: A
authors.lastname: Bettaïeb
authors.forename: I
authors.initials: I
authors.lastname: Plo
authors.forename: V
authors.initials: V
authors.lastname: Mansat-De Mas
authors.forename: A
authors.initials: A
authors.lastname: Quillet-Mary
authors.forename: T
authors.initials: T
authors.lastname: Levade
authors.forename: G
authors.initials: G
authors.lastname: Laurent
authors.forename: J P
authors.initials: JP
authors.lastname: Jaffrézou
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D001952:Bridged-Ring Compounds / Q000494:pharmacology; D002518:Ceramides / Q000096:biosynthesis*; D053938:DNA Fragmentation / Q000187:drug effects; D003630:Daunorubicin / Q000494:pharmacology*; D004075:Diglycerides / Q000502:physiology*; D006801:Humans; D006868:Hydrolysis; D008942:Mitoxantrone / Q000494:pharmacology*; D009636:Norbornanes; D010713:Phosphatidylcholines / Q000378:metabolism*; D011493:Protein Kinase C / Q000378:metabolism; D013859:Thiocarbamates; D013871:Thiones / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D001952:Bridged-Ring Compounds; D002518:Ceramides; D004075:Diglycerides; D009636:Norbornanes; D010713:Phosphatidylcholines; D013859:Thiocarbamates; D013871:Thiones; C046498:tricyclodecane-9-yl-xanthogenate; D008942:Mitoxantrone; D011493:Protein Kinase C; D003630:Daunorubicin